Latest News and Press Releases

New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...

Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae.

Wilmington, Delaware, United States, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - According to TMR, gonorrhea therapeutics are expected to expand at a 5.3% CAGR from 2019...

Los Angeles, USA, March 24, 2021 (GLOBE NEWSWIRE) -- Gonorrhea Pipeline Analysis: Emerging Therapies and Key Companies Transforming the Gonorrhea Landscape  Gonorrhea Pipeline report provides...

Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford,...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US,...

Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...

Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant...

SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted...